<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02005211</url>
  </required_header>
  <id_info>
    <org_study_id>D5010C00003</org_study_id>
    <nct_id>NCT02005211</nct_id>
  </id_info>
  <brief_title>A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Healthy Japanese Male and Non-Fertile Female Volunteers Including Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts, ie, single dose part with young healthy subjects (Part 1)
      and single and multiple dose part with elderly healthy subjects (Part 2), to assess the
      safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3293 following single and
      multiple ascending dose administration to healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, randomised, double-blind, placebo-controlled, single centre study to
      assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3293 following
      single and multiple ascending dose administration to healthy subjects. This study consists of
      two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple
      dose part with elderly healthy subjects (Part 2). The study design allows a gradual
      escalation of dosage levels between sequential cohorts with safety monitoring to ensure the
      safety of the healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Adverse Events</measure>
    <time_frame>Day of first dose to follow up</time_frame>
    <description>Safety - Number of subjects reporting any adverse events during the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Cmax - Overall Study</measure>
    <time_frame>0, 0.5,1,2,3,4,8,12,24,48 hr single dose, multiple dose does not include 48 hr</time_frame>
    <description>Pharmacokinetic maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK AUC - Overall Study (SAD &amp; MAD Parts)</measure>
    <time_frame>0,0.5,1,2,3,4,8,12,24,48 hr single dose, multiple dose does not include 48 hr</time_frame>
    <description>Pharmacokintic Area Under the Curve (0 to t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker</measure>
    <time_frame>Pre dose vs Day 14</time_frame>
    <description>Biomarker (Abeta 1-40; A beta 1-42) % change from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers</condition>
  <arm_group>
    <arm_group_label>AZD3293</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given (2 subjects in each cohort)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3293</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>AZD3293</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese elderly and young males and females (of non-childbearing potential)

          -  Body mass index (BMI) between 17 and 27 kg/m2 and weigh at least 40 kg and no more
             than 100 kg

        Exclusion Criteria:

          -  Psychiatric disease/condition, GI, renal, hepatic, cardiovascular, psychiatric, or
             retinal diseases or disorders

          -  Use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs.

          -  Frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other
             nicotine products.

          -  Neurological disease, including seizures, recent memory impairment, or clinically
             significant head injury.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Alexander, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kei Sakamoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sugioka Memorial Hospital, Medical Co. LTA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2013</study_first_posted>
  <results_first_submitted>October 13, 2015</results_first_submitted>
  <results_first_submitted_qc>October 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2015</results_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD3293</keyword>
  <keyword>Healthy volunteers</keyword>
  <keyword>Young volunteers</keyword>
  <keyword>Elderly volunteers</keyword>
  <keyword>Japanese volunteers</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Single and multiple ascending dose study</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy subjects, adult and elderly Japanese vlounteers, male and female (non-fertile); First patient enrolled 24 Dec 2013, last patient completed 29 Jul 2014</recruitment_details>
      <pre_assignment_details>Single Japanese Centre: SAD Part 1: 24 young adult subjects in 3 cohorts of 8, 2 placebo and 6 active AZD3293 dose (15 mg, 50 mg, 150 mg); MAD Part 2:16 elderly subjects in 2 Cohorts of 8, randomized 2 placebo and 6 active dose AZD3293 (15 mg, 50 mg) - Only data on subjests enrolled into cohorts was included in the data base for reporting</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Part 1</title>
          <description>Placebo Part 1 - SAD</description>
        </group>
        <group group_id="P2">
          <title>AZD3293 15 mg Part 1</title>
          <description>AZD3293 15 mg Part 1 - SAD</description>
        </group>
        <group group_id="P3">
          <title>AZD3293 50 mg Part 1</title>
          <description>AZD3293 50 mg Part 1 - SAD</description>
        </group>
        <group group_id="P4">
          <title>AZD3293 150 mg Part 1</title>
          <description>AZD3293 150 mg Part 1 - SAD</description>
        </group>
        <group group_id="P5">
          <title>AZD3293 15 mg Part 2</title>
          <description>AZD3293 15 mg Part 2 -MAD</description>
        </group>
        <group group_id="P6">
          <title>AZD3293 50 mg Part 2</title>
          <description>AZD3293 50 mg Part 2 - MAD</description>
        </group>
        <group group_id="P7">
          <title>Placebo Part 2</title>
          <description>Placebo Part 2 - MAD</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 - Cohorts 1-3 Adult Subjects</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 - Elderly Subjects Cohorts 4 &amp; 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Part 1 - Single Ascending Dose - healthy adults, Part 2 - Multiple Ascending Doses - healthy elderly</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Part 1</title>
          <description>Placebo Part 1 - SAD</description>
        </group>
        <group group_id="B2">
          <title>AZD3293 15 mg Part 1</title>
          <description>AZD3293 15 mg Part 1 - SAD</description>
        </group>
        <group group_id="B3">
          <title>AZD3293 50 mg Part 1</title>
          <description>AZD3293 50 mg Part 1 - SAD</description>
        </group>
        <group group_id="B4">
          <title>AZD3293 150 mg Part 1</title>
          <description>AZD3293 150 mg Part 1 - SAD</description>
        </group>
        <group group_id="B5">
          <title>AZD3293 15 mg Part 2</title>
          <description>AZD3293 15 mg Part 2 -MAD</description>
        </group>
        <group group_id="B6">
          <title>AZD3293 50 mg Part 2</title>
          <description>AZD3293 50 mg Part 2 - MAD</description>
        </group>
        <group group_id="B7">
          <title>Placebo Part 2</title>
          <description>Placebo Part 2 - MAD</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at study enrollment</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Young adult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="9.1" lower_limit="20" upper_limit="42"/>
                    <measurement group_id="B2" value="32.2" spread="9.7" lower_limit="22" upper_limit="46"/>
                    <measurement group_id="B3" value="23.8" spread="5.0" lower_limit="21" upper_limit="34"/>
                    <measurement group_id="B4" value="22.7" spread="3.3" lower_limit="20" upper_limit="29"/>
                    <measurement group_id="B5" value="NA">Elderly</measurement>
                    <measurement group_id="B6" value="NA" lower_limit="59" upper_limit="70">Elderly</measurement>
                    <measurement group_id="B7" value="NA" lower_limit="56" upper_limit="68">Elderly</measurement>
                    <measurement group_id="B8" value="26.9" spread="7.8" lower_limit="56" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elderly Adults</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Young</measurement>
                    <measurement group_id="B2" value="NA">Young</measurement>
                    <measurement group_id="B3" value="NA">Young</measurement>
                    <measurement group_id="B4" value="NA">Young</measurement>
                    <measurement group_id="B5" value="65.5" spread="3.8" lower_limit="59" upper_limit="71"/>
                    <measurement group_id="B6" value="64.2" spread="5.0"/>
                    <measurement group_id="B7" value="60.5" spread="5.4"/>
                    <measurement group_id="B8" value="63.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>PK Cmax - Overall Study</title>
        <description>Pharmacokinetic maximum concentration</description>
        <time_frame>0, 0.5,1,2,3,4,8,12,24,48 hr single dose, multiple dose does not include 48 hr</time_frame>
        <population>Pharmacokinetic</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3293 15 mg Part 1</title>
            <description>AZD3293 15 mg Part 1 - SAD</description>
          </group>
          <group group_id="O2">
            <title>AZD3293 50 mg Part 1</title>
            <description>AZD3293 50 mg Part 1 - SAD</description>
          </group>
          <group group_id="O3">
            <title>AZD3293 150 mg Part 1</title>
            <description>AZD3293 150 mg Part 1 - SAD</description>
          </group>
          <group group_id="O4">
            <title>AZD3293 15 mg Part 2</title>
            <description>AZD3293 15 mg Part 2 -MAD</description>
          </group>
          <group group_id="O5">
            <title>AZD3293 50 mg Part 2</title>
            <description>AZD3293 50 mg Part 2 - MAD</description>
          </group>
        </group_list>
        <measure>
          <title>PK Cmax - Overall Study</title>
          <description>Pharmacokinetic maximum concentration</description>
          <population>Pharmacokinetic</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" spread="20.9"/>
                    <measurement group_id="O2" value="395" spread="24.9"/>
                    <measurement group_id="O3" value="1480" spread="14.4"/>
                    <measurement group_id="O4" value="86.6" spread="31.7"/>
                    <measurement group_id="O5" value="395" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAD -Day 10 steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="115" spread="29.7"/>
                    <measurement group_id="O5" value="465" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAD - Day 14 steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="119" spread="23.3"/>
                    <measurement group_id="O5" value="502" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK AUC - Overall Study (SAD &amp; MAD Parts)</title>
        <description>Pharmacokintic Area Under the Curve (0 to t)</description>
        <time_frame>0,0.5,1,2,3,4,8,12,24,48 hr single dose, multiple dose does not include 48 hr</time_frame>
        <population>healthy Japanese participants</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3293 15 mg Part 1</title>
            <description>AZD3293 15 mg Part 1 - SAD</description>
          </group>
          <group group_id="O2">
            <title>AZD3293 50 mg Part 1</title>
            <description>AZD3293 50 mg Part 1 - SAD</description>
          </group>
          <group group_id="O3">
            <title>AZD3293 150 mg Part 1</title>
            <description>AZD3293 150 mg Part 1 - SAD</description>
          </group>
          <group group_id="O4">
            <title>AZD3293 15 mg Part 2</title>
            <description>AZD3293 15 mg Part 2 -MAD</description>
          </group>
          <group group_id="O5">
            <title>AZD3293 50 mg Part 2</title>
            <description>AZD3293 50 mg Part 2 - MAD</description>
          </group>
        </group_list>
        <measure>
          <title>PK AUC - Overall Study (SAD &amp; MAD Parts)</title>
          <description>Pharmacokintic Area Under the Curve (0 to t)</description>
          <population>healthy Japanese participants</population>
          <units>hr.ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839" spread="28.1"/>
                    <measurement group_id="O2" value="2810" spread="17.6"/>
                    <measurement group_id="O3" value="10700" spread="10.1"/>
                    <measurement group_id="O4" value="877" spread="12.5"/>
                    <measurement group_id="O5" value="3070" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAD -Day 10 Steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="1060" spread="18.3"/>
                    <measurement group_id="O5" value="3540" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MAD -Day 14 Steady state</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="1030" spread="12.8"/>
                    <measurement group_id="O5" value="3280" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarker</title>
        <description>Biomarker (Abeta 1-40; A beta 1-42) % change from baseline</description>
        <time_frame>Pre dose vs Day 14</time_frame>
        <population>Pharmacodynamic</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Part 1</title>
            <description>Placebo Part 1 - SAD</description>
          </group>
          <group group_id="O2">
            <title>AZD3293 15 mg Part 1</title>
            <description>AZD3293 15 mg Part 1 - SAD</description>
          </group>
          <group group_id="O3">
            <title>AZD3293 50 mg Part 1</title>
            <description>AZD3293 50 mg Part 1 - SAD</description>
          </group>
          <group group_id="O4">
            <title>AZD3293 150 mg Part 1</title>
            <description>AZD3293 150 mg Part 1 - SAD</description>
          </group>
          <group group_id="O5">
            <title>AZD3293 15 mg Part 2</title>
            <description>AZD3293 15 mg Part 2 -MAD</description>
          </group>
          <group group_id="O6">
            <title>AZD3293 50 mg Part 2</title>
            <description>AZD3293 50 mg Part 2 - MAD</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part 2</title>
            <description>Placebo Part 2 - MAD</description>
          </group>
        </group_list>
        <measure>
          <title>Biomarker</title>
          <description>Biomarker (Abeta 1-40; A beta 1-42) % change from baseline</description>
          <population>Pharmacodynamic</population>
          <units>% change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma Abeta(1-40), Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.03" spread="14.3"/>
                    <measurement group_id="O2" value="-69.6" spread="8.36"/>
                    <measurement group_id="O3" value="-75.8" spread="6.34"/>
                    <measurement group_id="O4" value="-62.7" spread="37.6"/>
                    <measurement group_id="O5" value="-65.9" spread="4.54"/>
                    <measurement group_id="O6" value="-70.2" spread="3.76"/>
                    <measurement group_id="O7" value="-7.4" spread="3.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Abeta (1-42) Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80" spread="9.78"/>
                    <measurement group_id="O2" value="-58.3" spread="22.3"/>
                    <measurement group_id="O3" value="-71.9" spread="9.74"/>
                    <measurement group_id="O4" value="-79.4" spread="4.84"/>
                    <measurement group_id="O5" value="-73.7" spread="4.03"/>
                    <measurement group_id="O6" value="-77.1" spread="5.31"/>
                    <measurement group_id="O7" value="12.4" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Abeta(1-40) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O5" value="-74.7" spread="5.28"/>
                    <measurement group_id="O6" value="-77.0" spread="3.36"/>
                    <measurement group_id="O7" value="-5.1" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF Abeta(1-40) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O5" value="-50.4" spread="7.49"/>
                    <measurement group_id="O6" value="-76.6" spread="3.96"/>
                    <measurement group_id="O7" value="-8.0" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF Abeta(1-42) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O5" value="-63.2" spread="9.12"/>
                    <measurement group_id="O6" value="-79.3" spread="4.69"/>
                    <measurement group_id="O7" value="1.75" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Abeta(1-42) Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O2" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O3" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O4" value="NA">PART 1 - Single dose</measurement>
                    <measurement group_id="O5" value="-77.6" spread="4.73"/>
                    <measurement group_id="O6" value="-78.6" spread="4.27"/>
                    <measurement group_id="O7" value="15.9" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety - Adverse Events</title>
        <description>Safety - Number of subjects reporting any adverse events during the study</description>
        <time_frame>Day of first dose to follow up</time_frame>
        <population>Safety</population>
        <group_list>
          <group group_id="O1">
            <title>AZD3293 15 mg Part 1</title>
            <description>AZD3293 15 mg Part 1 - SAD</description>
          </group>
          <group group_id="O2">
            <title>AZD3293 50 mg Part 1</title>
            <description>AZD3293 50 mg Part 1 - SAD</description>
          </group>
          <group group_id="O3">
            <title>AZD3293 150 mg Part 1</title>
            <description>AZD3293 150 mg Part 1 - SAD</description>
          </group>
          <group group_id="O4">
            <title>AZD3293 15 mg Part 2</title>
            <description>AZD3293 15 mg Part 2 -MAD</description>
          </group>
          <group group_id="O5">
            <title>AZD3293 50 mg Part 2</title>
            <description>AZD3293 50 mg Part 2 - MAD</description>
          </group>
          <group group_id="O6">
            <title>Placebo Part 1</title>
            <description>Placebo Part 1 - SAD</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part2</title>
            <description>Placebo Part 2 - MAD</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Adverse Events</title>
          <description>Safety - Number of subjects reporting any adverse events during the study</description>
          <population>Safety</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 10 days after last dose, for Part 1: 7 to 10 days; for Part 2: 21 to 24 days</time_frame>
      <desc>Treatment emergent AEs were recorded from day of 1st dose</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Part 1</title>
          <description>Placebo Part 1 - SAD</description>
        </group>
        <group group_id="E2">
          <title>AZD3293 15 mg Part 1</title>
          <description>AZD3293 15 mg Part 1 - SAD</description>
        </group>
        <group group_id="E3">
          <title>AZD3293 50 mg Part 1</title>
          <description>AZD3293 50 mg Part 1 - SAD</description>
        </group>
        <group group_id="E4">
          <title>AZD3293 150 mg Part 1</title>
          <description>AZD3293 150 mg Part 1 - SAD</description>
        </group>
        <group group_id="E5">
          <title>AZD3293 15 mg Part 2</title>
          <description>AZD3293 15 mg Part 2 -MAD</description>
        </group>
        <group group_id="E6">
          <title>AZD3293 50 mg Part 2</title>
          <description>AZD3293 50 mg Part 2 - MAD</description>
        </group>
        <group group_id="E7">
          <title>Placebo Part 2</title>
          <description>Placebo Part 2 - MAD</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Medra</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharengitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Neuroscience iMed</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

